The Global Pain Therapeutics Market - Market Analysis, R&D Pipelines and Competitive Landscape

Table of Contents

1 METHODOLOGY AND EXECUTIVE SUMMARY

• 1.1 Research Methodology
• 1.2 Report Objectives and Scope
• 1.3 Executive Summary

2 CAUSES, CLASSIFICATIONS AND GLOBAL IMPACT OF PAIN

• 2.1 Causes
  • 2.1.1 Terminal Illness
  • 2.1.2 Pain and Genetics
  • 2.1.3 The Immune System and Pain
  • 2.1.4 The Subjective Nature of Pain
  • 2.1.5 Pain Transmission
    • 2.1.5.1 Nociceptors
    • 2.1.5.2 Pain Receptors
• 2.2 Classifications of Pain
  • 2.2.1 Chronic Pain
  • 2.2.2 Acute Pain
• 2.3 The Impact of Pain
  • 2.3.1 Demographic Impact of Pain
  • 2.3.2 Financial Cost of Pain

3 TREATING PAIN: DRUG CLASSES AND GUIDELINES

• 3.1 NSAIDs
• 3.2 Opioids
  • 3.2.1 Chronic Pain and Opioids
• 3.3 Antidepressants
• 3.4 Anticonvulsants

4 POST-OPERATIVE PAIN OVERVIEW AND THERAPEUTIC OPTIONS

• 4.1 Impact of Post-operative Pain
• 4.2 Pain Intensity in Surgical Sites
• 4.3 Site-Specific Pain Relief
• 4.4 Post-operative Medications
  • 4.4.1 Naropin
  • 4.4.2 DepoDur, DepoMorphine and Propofol
  • 4.4.3 Other Opioids for Pain Management
  • 4.4.4 NSAIDs for Post-operative Pain

5 BACK PAIN OVERVIEW AND THERAPEUTIC OPTIONS

• 5.1 Sciatica
• 5.2 Facet Joint Problems
• 5.3 Osteoarthritis
• 5.4 Diseases and Back Pain
• 5.5 Low Back Pain
• 5.6 Pharmaceutical Relief for Back Pain
  • 5.6.1 Transdermal Patches
  • 5.6.2 Injections for Back Pain
  • 5.6.3 Back Pain and Opioids
  • 5.6.4 Tricyclic Antidepressants
  • 5.6.5 Muscle Relaxers
  • 5.6.6 Colchicine
  • 5.6.7 Chronic Low Back Pain and Anticonvulsants

6 NEUROPATHIC PAIN OVERVIEW AND THERAPEUTIC OPTIONS

• 6.1 Nociceptive Versus Neuropathic Pain
• 6.2 Nociceptive and Neuropathic Mixed Pain
• 6.3 Neuropathic Pain Generation
• 6.4 Treating Neuropathic Pain
  • 6.4.1 Tricyclic Antidepressants
  • 6.4.2 Duloxetine
  • 6.4.3 Transdermal Fentanyl
  • 6.4.4 Tramadol
  • 6.4.5 Ketamine and Alfentanil
  • 6.4.6 Neurontin
  • 6.4.7 Lyrica
  • 6.4.8 Carbamazepine
  • 6.4.9 Lidocaine

7 MIGRAINE OVERVIEW AND THERAPEUTIC OPTIONS

• 7.1 Impact of Migraines
• 7.2 Pharmacological Treatment of Migraine Pain
  • 7.2.1 Fiorinal and Fioricet
  • 7.2.2 Ergot Alkaloid Derivatives
  • 7.2.3 Triptans
    • 7.2.3.1 Comparing Triptans
    • 7.2.3.2 Imitrex
    • 7.2.3.3 Zomig
    • 7.2.3.4 Maxalt
    • 7.2.3.5 Relpax
  • 7.2.4 Neuroleptics
  • 7.2.5 Beta-Blockers
• 7.3 Alternative Therapies for Migraine

8 CANCER PAIN OVERVIEW AND THERAPEUTIC OPTIONS

• 8.1 Causes of Cancer Pain
• 8.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Cancer Pain
• 8.3 Opioids and Cancer Pain
  • 8.3.1 Reluctance to Prescribe Opioids
• 8.4 Seizure Drugs for Cancer Pain

9 ARTHRITIC PAIN OVERVIEW AND THERAPEUTIC OPTIONS

• 9.1 Impact of Arthritis
• 9.2 Rheumatoid Arthritis
  • 9.2.1 Causes
  • 9.2.2 RA Demographics
  • 9.2.3 Genetic Susceptibility
  • 9.2.4 Environmental Factors
  • 9.2.5 High Cost of Rheumatoid Arthritis
• 9.3 Osteoarthritis
  • 9.3.1 Causes
  • 9.3.2 Pharmacological Treatment of Osteoarthritis
    • 9.3.2.1 Cox-2 Class
  • 9.3.3 Pharmacological Treatment of Rheumatoid Arthritis
• 9.4 Antirheumatic Drug Classes
  • 9.4.1 Nonsteroidal Anti-Inflammatory Drugs
  • 9.4.2 Corticosteroids

10 FIBROMYALGIA OVERVIEW AND THERAPEUTIC OPTIONS

• 10.1 Manifestations
• 10.2 Impact of Fibromyalgia
• 10.3 Natural Treatments for Fibromyalgia
• 10.4 Prescription Treatments for Fibromyalgia
  • 10.4.1 Treatment with Antidepressants
  • 10.4.2 Muscle Relaxants
  • 10.4.3 Sleep Modifiers
  • 10.4.4 Anxiety Medications
  • 10.4.5 Anticonvulsants
  • 10.4.6 Antibiotics

11 NON-PHARMACEUTICAL PAIN TREATMENT

• 11.1 Acupuncture
  • 11.1.1 Assessing Acupuncture' s Value
• 11.2 Osteopathic Manipulation
  • 11.2.1 Osteopathic Treatment
  • 11.2.2 Conditions Treated by Osteopaths
• 11.3 Physiotherapy
• 11.4 Reflexology
• 11.5 Neurostructural Integration Technique
• 11.6 Herbal Medicine
• 11.7 Neurolytic Block Injections
  • 11.7.1 Examples of Neurolytic Blocks
• 11.8 Chemical Neurolytic Blocks
• 11.9 Cryoablation
• 11.10 Radiofrequency Lesioning
• 11.11 Neurosurgical Procedures
• 11.12 Chemical Ablation
• 11.13 Nerve Blocks
• 11.14 Neurostimulation and Pain Control
• 11.15 Electro Thermal Disc Decompression/ Intradiscal Electro Thermocoagulation
• 11.16 Selective Nerve Root Injections
• 11.17 Facet Joint Pain Block
• 11.18 Trigger Spot Injections
• 11.19 Peripheral Nerve Injections
• 11.20 Cervical and Lumbar Epidural Blocks
• 11.21 Cognitive Behavioral Treatment (CBT)

12 NSAID USE AND MARKET ANALYSIS

• 12.1 Overview
• 12.2 Over-the-Counter NSAIDs
  • 12.2.1 Ibuprofen
  • 12.2.2 Naproxen
  • 12.2.3 Acetaminophen and Aspirin
• 12.3 Traditional Prescription NSAIDs
  • 12.3.1 Diclofenac/Cataflam/Voltaren
  • 12.3.2 Arthrotec
  • 12.3.3 Mobic
    • 12.3.3.1 Mobic' s Market Performance
    • 12.3.3.2 Mobic Vs Other NSAIDs
  • 12.3.4 DayPro
    • 12.3.4.1 Rheumatoid Arthritis Relief from DayPro
    • 12.3.4.2 Osteoarthritis Relief from DayPro
  • 12.3.5 Relafen
    • 12.3.5.1 Relafen Versus Naproxen and Aspirin
    • 12.3.5.2 Endoscopy Trials
• 12.4 The Future of the NSAID Market
• 12.5 Drivers and Constraints of the NSAID Market

13 OPIOID USE AND MARKET TRENDS

• 13.1 Drawbacks of Opioid Therapy
• 13.2 Treating Chronic Pain
• 13.3 Key Opioid Products
  • 13.3.1 Morphine
    • 13.3.1.1 Increased Usage of Morphine
    • 13.3.1.2 Cognitive and Psychomotor Effects
    • 13.3.1.3 Extended Release Morphine
      • 13.3.1.3.1 Kadian
        • 13.3.1.3.1.1 Kadian and Naltrexone
        • 13.3.1.3.1.2 Key Clinical Trial
  • 13.3.2 Codeine
  • 13.3.3 Oxycodone
  • 13.3.4 Vicodin
  • 13.3.5 Ultracet/Ultram
  • 13.3.6 Duragesic
  • 13.3.7 Fentora
  • 13.3.8 Ionsys
• 13.4 Legal Regulation of Opioids
• 13.5 Side Effects
• 13.6 Adjuvant Medications
• 13.7 Opioid Market Analysis
  • 13.7.1 OxyContin
    • 13.7.1.1 Abuse-Resistant OxyContin
    • 13.7.1.2 Generic Competition
  • 13.7.2 Duragesic
  • 13.7.3 Kadian
  • 13.7.4 Ultracet/Ultram
  • 13.7.5 Avinza
  • 13.7.6 Actiq
• 13.8 The Future of the Opioid Market
• 13.9 Drivers and Constraints of the Opioid Market

14 TRIPTANS THERAPY MARKET

• 14.1 Overview
• 14.2 Leading Migraine Therapies
  • 14.2.1 Imitrex/Imigran
  • 14.2.2 Zomig
  • 14.2.3 Relpax
  • 14.2.4 Maxalt
  • 14.2.5 Frova
• 14.3 Preventive vs. Abortive Therapy
• 14.4 The Future of the Migraine Market
• 14.5 Drivers and Constraints of the Triptan Therapy Market

15 ANTICONVULSANT MARKET

• 15.1 Overview
• 15.2 Leading Anticonvulsants
  • 15.2.1 Lyrica
  • 15.2.2 Neurontin
  • 15.2.3 Topamax
  • 15.2.4 Depakote
  • 15.2.5 Lamictal
  • 15.2.6 Trileptal
  • 15.2.7 Tegretol
• 15.3 The Future of the Anticonvulsant Market
• 15.4 Drivers and Constraints of the Anticonvulsant Market

16 COX-2 INHIBITORS AND THE FUTURE

• 16.1 The Fall of Bextra
  • 16.1.1 Post-Marketing Reports for Bextra
  • 16.1.2 Withdrawal of Bextra
• 16.2 The Fall of Vioxx
  • 16.2.1 Repercussions from the Vioxx Withdrawal
• 16.3 Celebrex: Surviving the Fallout
  • 16.3.1 Black Box Warning
• 16.4 Cox-2 Pipeline
  • 16.4.1 Prexige
    • 16.4.1.1 TARGET Assessment
    • 16.4.1.2 Future of Prexige
  • 16.4.2 Arcoxia
  • 16.4.3 Dynastat
• 16.5 The Future of the Cox-2 Class
• 16.6 Drivers and Constraints of the Cox-2 Market

17 PRODUCTS IN DEVELOPMENT

• 17.1 Key Opioid Products in Development
  • 17.1.1 Sufentanil Patches
  • 17.1.2 Chronogesic
  • 17.1.3 Remoxy
  • 17.1.4 Rapinyl
  • 17.1.5 Hydromorphone Patches
  • 17.1.6 M6G
• 17.2 Key Migraine Pain Therapies in Development
  • 17.2.1 AZ-001
  • 17.2.2 PRO-513
  • 17.2.3 MK-0974
  • 17.2.4 Botox
  • 17.2.5 Trexima
  • 17.2.6 Dysport
  • 17.2.7 NovaDel
  • 17.2.8 Zogenix
• 17.3 Key Cancer Pain Therapies in Development
  • 17.3.1 Rapinyl
  • 17.3.2 Remoxy
  • 17.3.3 Sativex
  • 17.3.4 Ziconatide
  • 17.3.5 Chronogesic Pain Therapy System
  • 17.3.6 ASICs
  • 17.3.7 Xen2174
• 17.4 Key Fibromyalgia Therapies in Development
  • 17.4.1 Cymbalta
  • 17.4.2 Pristiq (desvenlafaxine)
  • 17.4.3 Milnacipran
  • 17.4.4 Xyrem (sodium oxybate)
  • 17.4.5 Other Fibromyalgia Research Areas
• 17.5 Key Post-operative Pain Therapies in Development
  • 17.5.1 LidoPAIN SP
  • 17.5.2 Dyloject
  • 17.5.3 M6G
  • 17.5.4 ROX-888
• 17.6 Key Neuropathic Pain Therapies in Development
  • 17.6.1 Fentora
  • 17.6.2 NGX-4010
  • 17.6.3 NP-1
  • 17.6.4 Cannabinor (CB2) IV
  • 17.6.5 V3381
• 17.7 Emerging Novel Drug Classes
• 17.8 Comparative Analysis of Emerging Therapies

18 THE ROLE OF DRUG DELIVERY IN EMERGING PAIN THERAPEUTICS

• 18.1 Delivery Options for Pain Therapeutics
• 18.2 Emerging Technologies for Delivery of Pain Therapeutics
  • 18.2.1 Delivery Devices
  • 18.2.2 More Convenient Administration Routes

19 PROMISING AREAS OF RESEARCH

• 19.1 Natural Painkillers
• 19.2 Peptides
• 19.3 Epibatidine
• 19.4 Willow Bark
• 19.5 Chilli Peppers and Capsaicin
• 19.6 Cannabinoids
• 19.7 Receptors as Gateways
• 19.8 Chromaffin Cells
• 19.9 Homeopathic Remedies
• 19.10 Ion Channels
  • 19.10.1 Calcium Channel Blockers
    • 19.10.1.1 Case Study: Prialt
  • 19.10.2 Sodium Channel Blockers
    • 19.10.2.1 Tetrodotoxin
  • 19.10.3 Vanilloid Receptors
  • 19.10.4 Glutamate Receptor Antagonists
    • 19.10.4.1 NMDA-Receptor Antagonists
• 19.11 NSRI Agents

20 COMPANY BRIEFS

• 20.1 Abbott Laboratories
• 20.2 Alexza Pharmaceuticals
• 20.3 Alpharma
• 20.4 Altea Therapeutics
• 20.5 Amgen
• 20.6 Anesiva
• 20.7 Aradigm
• 20.8 Argolyn Bioscience
• 20.9 AstraZeneca
• 20.10 Avigen
• 20.11 Bayer Schering
• 20.12 Baxter
• 20.13 Biogen Idec
• 20.14 Biovail
• 20.15 Boehringer Ingelheim
• 20.16 Bristol-Myers Squibb
• 20.17 Cadence Pharmaceuticals
• 20.18 CeNeS Pharmaceuticals
• 20.19 Cephalon
• 20.20 Cerimon Pharmaceuticals
• 20.21 Cipher Pharmaceuticals
• 20.22 CombinatoRx
• 20.23 Cypress Bioscience
• 20.24 Depomed
• 20.25 Durect Corporation
• 20.26 Eisai
• 20.27 Elan Pharmaceuticals
• 20.28 Eli Lilly
• 20.29 Elite Pharmaceuticals
• 20.30 Endo Pharmacuticals
• 20.31 Enhance Biotech (formerly Ardent Pharma)
• 20.32 EpiCept
• 20.33 Evotec Neurosciences
• 20.34 FemmePharma Global Healthcare
• 20.35 Forest Laboratories
• 20.36 GlaxoSmithKline
• 20.37 GW Pharmaceuticals
• 20.38 Horizon Therapeutics
• 20.39 Icagen
• 20.40 Indevus Pharmaceuticals
• 20.41 Innocoll Pharma
• 20.42 Ista Pharmaceuticals
• 20.43 Javelin Pharmaceuticals
• 20.44 Johnson & Johnson
• 20.45 Kalypsys
• 20.46 King Pharmaceuticals
• 20.47 Labopharm
• 20.48 Medtronic
• 20.49 Merck & Co
• 20.50 MGI Pharma
• 20.51 Nastech Pharmaceutical
• 20.52 NeuroCure
• 20.53 Neurocrine Biosciences
• 20.54 NeurogesX
• 20.55 Neuromed Pharmaceuticals
• 20.56 Neurorecovery
• 20.57 NovaDel
• 20.58 Novartis Pharmaceuticals
• 20.59 Noven
• 20.60 Nuvo Research
• 20.61 Organon
• 20.62 PainCeptor Pharma
• 20.63 Pain Therapeutics
• 20.64 Penwest
• 20.65 Pfizer
• 20.66 Pharmos
• 20.67 Phosphagenics
• 20.68 Pozen
• 20.69 ProEthic Pharmaceuticals
• 20.70 Purdue
• 20.71 Questcor Pharmaceuticals
• 20.72 Quigley Pharma
• 20.73 Renovis
• 20.74 Roche
• 20.75 RoxRo Pharma
• 20.76 Sanofi-Aventis
• 20.77 Sepracor
• 20.78 SkyePharma
• 20.79 Sosei
• 20.80 Symbollon
• 20.81 Tanabe Seiyaku
• 20.82 Targacept
• 20.83 TheraQuest Biosciences
• 20.84 TorreyPines Therapeutics
• 20.85 UCB Pharma
• 20.86 Vernalis
• 20.87 Vertex Pharmaceuticals
• 20.88 Victory Pharma
• 20.89 Wex Pharmaceuticals
• 20.90 Wyeth
• 20.91 Xenome
• 20.92 XenoPort
• 20.93 XTL Biopharmaceuticals
• 20.94 YM Biosciences
• 20.95 ZARS Pharma
• 20.96 Zogenix

APPENDICES

• APPENDIX I
• APPENDIX II
• APPENDIX III

TABLES

• Table 1.1 Value of the Pain Market by Therapeutic Class 2004 and 2006 ($ mn)
• Table 1.2 Top 20 Pain Medications Worldwide in 2006 ($ mn)
• Table 2.1 Characteristics and Treatment of Acute vs Chronic Pain
• Table 2.2 Incidence of Pain Conditions in American Households
• Table 3.1 Key Pain Management Drug Classes and Diseases/Conditions Treated
• Table 3.2 NSAID Delivery Routes
• Table 3.3 Traditional NSAIDs
• Table 3.4 The Oxford League Table of Analgesic Efficacy
• Table 3.5 Opioid Delivery Routes
• Table 3.6 Well-Known Narcotic Analgesics
• Table 3.7 Antidepressant Delivery Routes
• Table 3.8 WHO Guidelines for Pain Therapy
• Table 4.1 WFSA Analgesic Ladder
• Table 6.1 Common Etiologies of Neuropathic Pain
• Table 6.2 Drug Interactions of the Agents Used to Treat Neuropathic Pain
• Table 7.2 Popular Medicines for the Treatment of Migraine
• Table 7.3 Preventive Headache Therapies
• Table 7.4 Common Analgesics Prescribed for Mild Migraine Pain
• Table 7.5 Ergot Alkaloid Derivatives for Migraine Pain
• Table 7.6 NSAIDs and Cox-2 Inhibitors for Migraine Pain
• Table 7.7 Triptans for Migraine Pain
• Table 7.8 Patent Expirations for Leading Triptans
• Table 8.1 Cancer Pain and Therapeutic Options
• Table 8.2 Adjuvants to Opioids for Treating Cancer Pain
• Table 8.3 Other Treatments for Cancer Pain
• Table 8.4 Anticonvulsants for Cancer Pain
• Table 9.1 Leading Causes of Years of Life Lost Due to a Disability for Both Sexes of All Ages
• Table 9.2 Financial Impact of Employees Suffering RA
• Table 10.1 Popular Treatments for Fibromyalgia
• Table 11.1 Complementary and Alternative Medicine Use by US Adults (2002)
• Table 11.2 Ten Most Common Complementary and Alternative Therapies (2002)
• Table 11.3 Disease/Condition Most Frequently Treated with Complementary/Alternative Medicines
• Table 12.1 Global Sales of Leading Prescription NSAIDs (Traditional) 2006
• Table 12.2 Cox-2 NSAIDs
• Table 12.3 Prescription and OTC Non-Selective NSAIDs
• Table 12.4 Sales of Advil* 2002-2006 ($mn)
• Table 12.5 Financial Forecast of Ibuprofen Sales 2007-2011 ($ mn)
• Table 12.6 Sales of Aleve 2002-2006 (€ mn)
• Table 12.7 Sales of Aspirin 2005-2006 (€ mn)
• Table 12.8 Sales of Excedrin* 2002-2004 ($ mn)
• Table 12.9 Sales of Voltaren 2003-2006 ($ mn)
• Table 12.10 Financial Forecast of Voltaren Sales 2007-2011 ($ mn)
• Table 12.11 Sales of Mobic 2003-2006 (€ mn)
• Table 12.12 Financial Forecast of Mobic Sales 2007-2011 ($ mn)
• Table 12.13 Adverse Events (%) Occurring in ≥2% of Mobic Patients in a 12-Week Osteoarthritis Placebo and Active-Controlled Trial
• Table 12.14 Financial Forecast of the NSAID Market 2007-2011 ($ mn)
• Table 13.1 Overview of Opioid Analgesics
• Table 13.2 Key Opioid Product Sales 2006
• Table 13.3 Global Sales of OxyContin 2003-2006 ($ mn)
• Table 13.4 Financial Forecast of OxyContin Sales 2007-2011 ($ mn)
• Table 13.5 Percent of US Household Population 12 Years and Older Reporting Past Month Non-Medical Use of Physchotherapeutics
• Table 13.6 Global Sales of Duragesic 2001-2006 ($ mn)
• Table 13.7 Financial Forecast of Duragesic Sales 2007-2011 ($ mn)
• Table 13.8 Global Sales of Kadian 2002-2006 ($ mn)
• Table 13.9 Global Sales of Ultracet/Ultram 2001-2006 ($ mn)
• Table 13.10 Global Sales of Avinza 2003-2006 ($ mn)
• Table 13.11 Global Sales of Actiq 2002-2006 ($ mn)
• Table 13.12 Financial Forecast of Actiq Sales 2007-2011 ($ mn)
• Table 13.13 Financial Forecast of the Global Opioid Market 2006-2006 ($ mn)
• Table 14.1 Sales of Triptan Drugs 2001-2006
• Table 14.2 Sales of Leading Migraine Therapies 2006
• Table 14.3 Sales of Imitrex/Imigran 2001-2006 ($ mn)
• Table 14.4 Financial Forecast of Imitrex/Imigran Sales 2007-2011 ($ mn)
• Table 14.5 Sales of Zomig 2001-2006 ($ mn)
• Table 14.6 Financial Forecast of Zomig Sales 2007-2011 ($ mn)
• Table 14.7 Sales of Relpax 2001-2006 ($ mn)
• Table 14.8 Sales of Maxalt 2001-2006 ($ mn)
• Table 14.9 Sales of Frova 2005-2006 ($ mn)
• Table 14.10 Financial Forecast of Triptans 2007-2011 ($ mn)
• Table 15.1 Leading Anticonvulsants, Global Sales 2006
• Table 15.2 Sales Growth in the Anticonvulsants Market 2001-2006 ($ mn)
• Table 15.3 Leading Anticonvulsants Indications
• Table 15.4 Sales of Lyrica 2001-2006 ($ mn)
• Table 15.5 Financial Forecast of Lyrica Sales 2007-2011 ($ mn)
• Table 15.6 Sales of Neurontin 2001-2006 ($ mn)
• Table 15.7 Sales of Topamax 2001-2006 ($ mn)
• Table 15.8 Financial Forecast of Topamax Sales 2007-2011 ($ mn)
• Table 15.9 Sales of Depakote 2001-2006 ($ mn)
• Table 15.10 Financial Forecast of Depakote Sales 2007-2011 ($ mn)
• Table 15.11 Sales of Lamictal 2001-2006 ($ mn)
• Table 15.12 Financial Forecast of Lamictal Sales 2007-2011 ($ mn)
• Table 15.13 Sales of Trileptal 2001-2006 ($ mn)
• Table 15.14 Sales of Tegretol 2001-2006 ($ mn)
• Table 15.15 Financial Forecast of the Anticonvulsant Market 200-2011 ($ mn)
• Table 16.1 Leading Cox-2 Inhibitors 2004 ($ mn)
• Table 16.2 Sales of Celebrex 2003-2006 ($ mn)
• Table 16.3 Sales of Arcoxia 2003-2006 ($ mn)
• Table 16.4 Post-Bextra Switching Trends
• Table 16.5 Future Sales of Celebrex
• Table 17.1 Migraine Drugs in Development
• Table 17.2 Other Fibromyalgia Treatments in Development
• Table 17.3 Promising Areas of Fibromyalgia Research
• Table 17.4 Key Pipeline Products and Their Potential in Pain Management
• Table 18.1 Most Common Delivery Routes for Pain Therapeutics
• Table 20.1 Alexza' s Pain Therapeutics Pipeline
• Table 20.2 Amgen' s Pain Therapeutics Pipeline
• Table 20.3 Avigen' s Pain Therapeutics Pipeline
• Table 20.4 Cadence' s Pain Therapeutics Pipeline
• Table 20.5 CeNeS Pharmaceuticals' Pain Therapeutics Pipeline
• Table 20.6 Depomed' s Therapeutics Pipeline
• Table 20.7 Durect' s Pain Therapeutics Pipeline
• Table 20.8 Eisai' s Pain Therapeutics Pipeline
• Table 20.9 Elite' s Pain Therapeutics Pipeline
• Table 20.10 Evotec' s Pain Therapeutics Pipeline
• Table 20.11 Horizon' s Pain Therapeutics Pipeline
• Table 20.12 Javelin Pharmaceuticals' Pain Therapeutics Pipeline
• Table 20.13 Kalypsys' Pain Therapeutics Pipeline
• Table 20.14 Pfizer' s Pain Therapeutics Pipeline
• Table 20.15 Pozen' s Pain Therapeutics Pipeline
• Table 20.16 Purdue' s Pain Therapeutics Portfolio
• Table 20.17 Victory' s Pain Therapeutics Pipeline
• Table 20.18 XenoPort' s Pain Therapeutics Pipeline
• Table I Global Sales of Leading Pain Management Drugs 2006
• Table II Key Pipeline Pain Therapeutics
• Table III Acute Pain Pipeline
• Table IV Chronic Pain Pipeline
• Table V Neuropathic Pain Pipeline
• Table VI Post-operative Pain Pipeline
• Table VII Migraine Pain Pipeline
• Table VIII Rheumatoid Arthritis Pain Pipeline
• Table IX Cancer Pain Pipeline
• Table X NSAIDs Affected by Newly Required Warning Labels

GRAPHS

• Graph 1.1 Pain Therapeutics Market Share by Class 2006
• Graph 2.1 Top Causes of Pain
• Graph 7.1 Difference in Prevalence of Migraine Headache among Men and Women by Age
• Graph 9.1 Percentage of Adults with Diabetes, Heart Disease, or High Blood Pressure Who Also Have Arthritis
• Graph 12.1 Prescription NSAID Product Market Share (Traditional vs Cox-2 Inhibitors) 2006
• Graph 12.2 Prescription NSAID Product Market Share 2006
• Graph 12.3 Sales of Advil 2002-2006
• Graph 12.4 Sales of Aleve 2002-2006
• Graph 12.5 Sales of Aspirin 2005-2006
• Graph 12.6 Global Sale of Excedrin 2002-2004
• Graph 12.7 Sales of Voltaren 2003-2006
• Graph 12.8 Sales of Mobic 2003-2006
• Graph 13.1 Global Market Share of Branded Opioid Products 2006
• Graph 13.3 Global Sales of OxyContin 2003-2006
• Graph 13.4 Global Sales of Duragesic 2001-2006
• Graph 13.5 Global Sales of Kadian 2002-2006
• Graph 13.3 Global Sales of Ultracet/Ultram 2001-2006
• Graph 13.7 Global Sales of Avinza 2003-2006
• Graph 13.8 Global Sales of Actiq 2002-2006
• Graph 13.9 Financial Forecast of the Global Opioid Market 2006-2006
• Graph 14.1 Sales of Triptan Drugs 2001-2006
• Graph 14.2 Leading Migraine Therapies, Market Share 2006
• Graph 14.3 Geographic Market Share of Leading Triptan-Based Migraine Therapies 2006
• Graph 14.4 Sales of Imitrex/Imigran 2001-2006
• Graph 14.5 Sales of Zomig 2001-2006
• Graph 14.6 Sales of Relpax 2001-2006
• Graph 14.7 Sales of Maxalt 2001-2006
• Graph 14.8 Sales of Frova 2005-2006
• Graph 15.1 Leading Anticonvulsants, Market Share 2006
• Graph 15.2 Sales Growth in the Anticonvulsants Market 2001-2006 ($ mn)
• Graph 15.3 Sales of Lyrica 2004-2006
• Graph 15.4 Sales of Neurontin 2001-2006
• Graph 15.5 Sales of Topamax 2001-2006
• Graph 15.6 Sales of Depakote 2001-2006
• Graph 15.7 Sales of Lamictal 2001-2006
• Graph 15.8 Sales of Trileptal 2001-2006
• Graph 15.9 Sales of Tegretol 2001-2006
• Graph 16.2 Sales of Arcoxia 2003-2006
• Graph 16.1 Sales of Celebrex 2003-2006